(Q34852971)

4 August 2017

title

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. (English)

1 reference

4 August 2017

D L Arnold

1

1 reference

4 August 2017

D Campagnolo

2

1 reference

4 August 2017

H Panitch

3

1 reference

4 August 2017

A Bar-Or

4

1 reference

4 August 2017

J Dunn

5

1 reference

4 August 2017

M S Freedman

6

1 reference

4 August 2017

S K Gazda

7

1 reference

4 August 2017

T Vollmer

8

1 reference

4 August 2017

publication date

7 October 2008

1 reference

4 August 2017

1 reference

4 August 2017

volume

255

1 reference

4 August 2017

issue

10

1 reference

4 August 2017

page(s)

1473-1478

1 reference

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0911-X

Mechanism of action of mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0911-X

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0911-X

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0911-X

Normalized accurate measurement of longitudinal brain change

21 January 2018

1 reference

12 December 2020

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

12 December 2020

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis

1 reference

12 December 2020

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

1 reference

12 December 2020

Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.

1 reference

12 December 2020

1 reference

12 December 2020

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

1 reference

12 December 2020

Glatiramer acetate for the treatment of multiple sclerosis

1 reference

12 December 2020

Mechanisms of immunomodulation by glatiramer acetate

1 reference

12 December 2020

Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor

1 reference

12 December 2020

The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice

1 reference

12 December 2020

A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions

1 reference

12 December 2020

Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype.

1 reference

12 December 2020

10.1007/S00415-008-0911-X

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1016875544

0 references

1 reference